Next Article in Journal
Examining the Pathoplastic Moderating Role of Education on the Association between Depressive Mood and Self-Rated Health among Cancer Survivors: A Population-Based Study
Previous Article in Journal
Multifocality and Multicentrality in Breast Cancer: Comparison of the Efficiency of Mammography, Contrast-Enhanced Spectral Mammography, and Magnetic Resonance Imaging in a Group of Patients with Primarily Operable Breast Cancer

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.

Article

The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis

1
Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5A5, Canada
2
Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5W9, Canada
3
London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON N6A 5W9, Canada
4
Department of Internal Medicine, Section of Hematology and Oncology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 4031-4041; https://doi.org/10.3390/curroncol28050342
Received: 15 June 2021 / Revised: 4 August 2021 / Accepted: 28 September 2021 / Published: 9 October 2021
(This article belongs to the Section Gastrointestinal Oncology)
There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX)(5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOLFOX had DFS rates of 76.9% and 71.2% at 3 and 5 years, respectively. OS rates were 86.4% and 76.7% at 3 and 5 years, respectively. Median RDI was 73.8% for capecitabine and 76.3% and 85.6% for the oxaliplatin and 5-FU components respectively. Based on a multivariate analysis in patients receiving FOLFOX, those with an oxaliplatin DI > 80% had improvements in DFS and OS compared to those with an oxaliplatin DI of ≤ 80%. Otherwise, there was no significant difference in DFS or OS when comparing patients who achieved an RDI or a DI of above versus below 80% in the patients receiving adjuvant chemotherapy for resected colon cancer.
Keywords: dose index; relative dose intensity; colon cancer dose index; relative dose intensity; colon cancer
MDPI and ACS Style

Lakkunarajah, S.; Breadner, D.A.; Zhang, H.; Yamanaka, E.; Warner, A.; Welch, S. The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis. Curr. Oncol. 2021, 28, 4031-4041. https://doi.org/10.3390/curroncol28050342

AMA Style

Lakkunarajah S, Breadner DA, Zhang H, Yamanaka E, Warner A, Welch S. The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis. Current Oncology. 2021; 28(5):4031-4041. https://doi.org/10.3390/curroncol28050342

Chicago/Turabian Style

Lakkunarajah, Suganija, Daniel A. Breadner, Hanbo Zhang, Ellen Yamanaka, Andrew Warner, and Stephen Welch. 2021. "The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis" Current Oncology 28, no. 5: 4031-4041. https://doi.org/10.3390/curroncol28050342

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop